These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36750252)

  • 1. Immunotherapy reverses glioma-driven dysfunction of immune system homeostasis.
    DiVita Dean B; Wildes T; Dean J; Yegorov O; Yang C; Shin D; Francis C; Figg JW; Sebastian M; Font LF; Jin D; Reid A; Moore G; Fernandez B; Wummer B; Kuizon C; Mitchell D; Flores CT
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36750252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma.
    Wildes TJ; Grippin A; Dyson KA; Wummer BM; Damiani DJ; Abraham RS; Flores CT; Mitchell DA
    Clin Cancer Res; 2018 Aug; 24(16):3955-3966. PubMed ID: 29712687
    [No Abstract]   [Full Text] [Related]  

  • 3. Different Human Immune Lineage Compositions Are Generated in Non-Conditioned NBSGW Mice Depending on HSPC Source.
    Hess NJ; Lindner PN; Vazquez J; Grindel S; Hudson AW; Stanic AK; Ikeda A; Hematti P; Gumperz JE
    Front Immunol; 2020; 11():573406. PubMed ID: 33193358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of early myeloid progenitors as immunosuppressive cells.
    Pu S; Qin B; He H; Zhan J; Wu Q; Zhang X; Yang L; Qu C; Zhou Z
    Sci Rep; 2016 Mar; 6():23115. PubMed ID: 26979287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Escape After Adoptive T-cell Therapy for Malignant Gliomas.
    Wildes TJ; Dyson KA; Francis C; Wummer B; Yang C; Yegorov O; Shin D; Grippin A; Dean BD; Abraham R; Pham C; Moore G; Kuizon C; Mitchell DA; Flores CT
    Clin Cancer Res; 2020 Nov; 26(21):5689-5700. PubMed ID: 32788225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas.
    Flores-Toro JA; Luo D; Gopinath A; Sarkisian MR; Campbell JJ; Charo IF; Singh R; Schall TJ; Datta M; Jain RK; Mitchell DA; Harrison JK
    Proc Natl Acad Sci U S A; 2020 Jan; 117(2):1129-1138. PubMed ID: 31879345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating hematopoietic stem and progenitor cells are myeloid-biased in cancer patients.
    Wu WC; Sun HW; Chen HT; Liang J; Yu XJ; Wu C; Wang Z; Zheng L
    Proc Natl Acad Sci U S A; 2014 Mar; 111(11):4221-6. PubMed ID: 24591638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitigating the prevalence and function of myeloid-derived suppressor cells by redirecting myeloid differentiation using a novel immune modulator.
    Oliver L; Alvarez R; Diaz R; Valdés A; Colligan SH; Nemeth MJ; Twum DYF; Fernández A; Fernández-Medina O; Carlson LM; Yu H; Eng KH; Hensen ML; Rábade-Chediak ML; Fernández LE; Lee KP; Perez L; Muhitch JB; Mesa C; Abrams SI
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36150744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Depletion of myeloid-derived suppressor cells during interleukin-12 immunogene therapy does not confer a survival advantage in experimental malignant glioma.
    Thaci B; Ahmed AU; Ulasov IV; Wainwright DA; Nigam P; Auffinger B; Tobias AL; Han Y; Zhang L; Moon KS; Lesniak MS
    Cancer Gene Ther; 2014 Jan; 21(1):38-44. PubMed ID: 24434573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-6 contributes to metastatic switch via the differentiation of monocytic-dendritic progenitors into prometastatic immune cells.
    Magidey-Klein K; Cooper TJ; Kveler K; Normand R; Zhang T; Timaner M; Raviv Z; James BP; Gazit R; Ronai ZA; Shen-Orr S; Shaked Y
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34140316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and function of myeloid-derived suppressor cells generated from mouse embryonic and hematopoietic stem cells.
    Zhou Z; French DL; Ma G; Eisenstein S; Chen Y; Divino CM; Keller G; Chen SH; Pan PY
    Stem Cells; 2010 Mar; 28(3):620-32. PubMed ID: 20073041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tracking the fate of adoptively transferred myeloid-derived suppressor cells in the primary breast tumor microenvironment.
    Sceneay J; Griessinger CM; Hoffmann SHL; Wen SW; Wong CSF; Krumeich S; Kneilling M; Pichler BJ; Möller A
    PLoS One; 2018; 13(4):e0196040. PubMed ID: 29677215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune microenvironment of gliomas.
    Gieryng A; Pszczolkowska D; Walentynowicz KA; Rajan WD; Kaminska B
    Lab Invest; 2017 May; 97(5):498-518. PubMed ID: 28287634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloid-derived suppressor cells in gliomas.
    Gieryng A; Kaminska B
    Contemp Oncol (Pozn); 2016; 20(5):345-351. PubMed ID: 28373814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myeloid-derived suppressor cells (MDSCs) in gliomas and glioma-development.
    Kohanbash G; Okada H
    Immunol Invest; 2012; 41(6-7):658-79. PubMed ID: 23017140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glioma-derived galectin-1 regulates innate and adaptive antitumor immunity.
    Verschuere T; Toelen J; Maes W; Poirier F; Boon L; Tousseyn T; Mathivet T; Gerhardt H; Mathieu V; Kiss R; Lefranc F; Van Gool SW; De Vleeschouwer S
    Int J Cancer; 2014 Feb; 134(4):873-84. PubMed ID: 23929302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LAL deficiency induced myeloid-derived suppressor cells as targets and biomarkers for lung cancer.
    Zhao T; Liu S; Hanna NH; Jalal S; Ding X; Wan J; Yan C; Du H
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36914206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of Hematopoietic Stem/Progenitor Cells Promotes Immunosuppression Within the Pre-metastatic Niche.
    Giles AJ; Reid CM; Evans JD; Murgai M; Vicioso Y; Highfill SL; Kasai M; Vahdat L; Mackall CL; Lyden D; Wexler L; Kaplan RN
    Cancer Res; 2016 Mar; 76(6):1335-47. PubMed ID: 26719537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CCR1 and CCR5 mediate cancer-induced myelopoiesis and differentiation of myeloid cells in the tumor.
    Zilio S; Bicciato S; Weed D; Serafini P
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35064009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Insights into the Multifaceted Role of Myeloid-Derived Suppressor Cells (MDSCs) in High-Grade Gliomas: From Metabolic Reprograming, Immunosuppression, and Therapeutic Resistance to Current Strategies for Targeting MDSCs.
    Lakshmanachetty S; Cruz-Cruz J; Hoffmeyer E; Cole AP; Mitra SS
    Cells; 2021 Apr; 10(4):. PubMed ID: 33919732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.